Parkinson’s disease currently affects nearly one million Americans with no specific known cause and no cure. Treatments have ...

Researchers say exercise and innovative treatments may help manage Parkinson's symptoms and delay disease progression, while ...

The world's largest-ever clinical trial of treatments to slow or stop the progression of Parkinson's disease has launched, ...

The world's largest clinical trial for Parkinson’s disease has commenced, aiming to identify treatments that can slow or halt ...

Researchers have discovered how a surface protein on brain cells, called Aplp1, can play a role in spreading material ...

Glovadalen, a novel D1 receptor positive allosteric modulator, is linked to improve OFF time in patients with Parkinson’s ...

Degradation studies indicated that about 82% of the implants disintegrated within seven days. Complete degradation of the ...

Previous applications of TUS were limited, as they were imprecise and too weak to target areas deeper in the brain. Parkinson ...

Roche RHHBY announced that it will advance pipeline candidate prasinezumab into phase III development for early-stage Parkinson’s disease. Roche has a licensing agreement with Prothena PRTA for ...

"Furthermore, patients with RLS who were not treated with dopamine agonists tended to be at increased risk of developing Parkinson's disease, whereas those who were treated with dopamine agonists ...

A new initiative is set to explore the potential of repurposing existing medications to combat the symptoms of both Alzheimer’s and Parkinson’s diseases, aiming to accelerate the discovery of novel ...

Benztropine, a drug prescribed for tremors in Parkinson’s disease, has shown promise against tuberculosis (TB) in both human cell and mouse models. The corresponding study was published in npj ...